Imagine trying to find a few specific needles in a massive haystack of blood cells. This technology uses sound waves to gently push blood cells aside and trap tiny biological messengers called exosomes. It's like using a sonic filter to grab the most important clues for diagnosing cancer or heart disease from a simple blood draw.
Isolating virus-sized exosomes from blood is extremely challenging, creating a bottleneck for early detection of cancer and cardiac diseases.
A polymer-based microfluidic chip using thin-film actuators and ultrasound to separate plasma from blood and enrich exosomes.
If you are a device manufacturer dealing with the difficulty of isolating nano-sized biomarkers from whole blood — this project developed a polymer-based microfluidic chip that separates plasma and enriches exosomes. This allows for the creation of faster, bedside diagnostic tools for cancer and cardiac diseases.
If you are a research lab dealing with low yields of extracellular vesicles during sample preparation — this project developed a scaled-up capturing device that captures many more exosomes. This increases the amount of usable biomarker material for disease research.
If you are a pharma company dealing with the need for precise biomarkers to track drug efficacy in liver or kidney diseases — this project developed a thin-film actuated chip for high-purity exosome enrichment. This provides a cleaner sample for analyzing how a patient is responding to treatment.
Based on available project data, the exact price is not listed, but the project is investigating new materials to make the devices less expensive to produce.
Yes, the project is focusing on making the technology possible to produce on a larger scale to reach all necessary research and diagnostic labs.
The consortium has found a new method to increase capacity and is currently looking into whether they can patent it.
The exosome separation cartridge is designed for use in research labs and as a component for future point-of-care diagnostic instruments.
The project period runs from 2023-01-01 to 2025-12-31, with some upgrades already released to current instruments.
The consortium is highly commercially oriented with a 50% industry ratio, consisting of 2 SMEs and 2 universities across 3 countries (SE, DK, IT). This balance suggests a strong pipeline from academic research (Lund University, DTU) to market application via AcouSort AB and Day One Srl.
Contact AcouSort AB in Sweden for licensing or partnership inquiries.
Contact us to explore integration of acoustofluidic chips into your diagnostic pipeline.
